KLP Kapitalforvaltning AS Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

KLP Kapitalforvaltning AS lifted its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 65.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,900 shares of the biotechnology company’s stock after purchasing an additional 4,300 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Capricor Therapeutics were worth $108,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Capricor Therapeutics by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after purchasing an additional 2,314 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Capricor Therapeutics by 10.9% in the 1st quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 2,822 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Capricor Therapeutics by 31.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 3,162 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Capricor Therapeutics by 4.4% during the 1st quarter. Bank of New York Mellon Corp now owns 87,720 shares of the biotechnology company’s stock valued at $832,000 after acquiring an additional 3,693 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Capricor Therapeutics by 8.1% during the 1st quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company’s stock valued at $473,000 after acquiring an additional 3,731 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CAPR. Jones Trading decreased their target price on Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday, June 25th. Piper Sandler reissued an “overweight” rating and issued a $20.00 target price on shares of Capricor Therapeutics in a research report on Friday, July 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Finally, Roth Capital reduced their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Capricor Therapeutics Stock Down 0.5%

CAPR stock opened at $6.37 on Wednesday. Capricor Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $22.90. The firm has a market cap of $291.22 million, a PE ratio of -3.88 and a beta of 0.68. The business has a 50 day moving average of $6.80 and a 200 day moving average of $8.77.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.